Clinical trial · Observational
Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)
METRICS Study: Metabolic Evaluation Through Resting Indirect Calorimetry in Bladder Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to learn more about energy needs and muscle function during treatment for bladder cancer. These insights can help improve future patient care. The study team found in a previous study that resting energy can be different than what estimates show. Patients with bladder cancer are known to suffer a decline in physical resilience over time. Monitoring patients to understand these changes better could help design future treatments with these vulnerabilities in mind.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To assess Resting Energy Expenditure (REE) changes across key treatment milestones.
- timeFrame
- From enrollment, prior to chemotherapy, to 3 weeks after radical cystectomy.
- description
- Resting Energy Expenditure (REE) will be measured using indirect calorimetry before and after chemotherapy and radical cystectomy and will be associated with clinical outcomes.
Secondary outcomes (8)
- measure
- Blood biomarkers
- timeFrame
- From enrollment, prior to chemotherapy, to 3 weeks after radical cystectomy.
- description
- Blood will be collected at study visits and growth differentiation factor-15 (GDF-15) concentration will be evaluated.
- measure
- Inflammation marker
- timeFrame
- From enrollment, prior to chemotherapy, to 3 weeks after radical cystectomy.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed cancer diagnosis * Scheduled for platinum-based chemotherapy followed by radical cystectomy * Adequate renal and cardiac function for platinum-based chemotherapy Exclusion Criteria: * Prior chemotherapy or radiotherapy for bladder cancer * Severe cardiac, renal, hepatic, respiratory or metabolic diseases * Pregnant or breastfeeding * Uncontrolled conditions that could affect study outcomes
References
Publications (0)
Data not yet available